Sichuan Kelun Pharmaceutical Co.Ltd(002422) on the evening of February 23, it was announced that the company had recently obtained the notice of approval for drug supplementary application for chemical drug "compound amino acid (15) dipeptide (2) injection" approved and issued by the State Drug Administration. After review, the drug passed the consistency evaluation of quality and efficacy of generic drugs.
According to the announcement, compound amino acid (15) dipeptide (2) injection is an parenteral nutrition preparation, which is applied to patients who can not supplement nutrition orally or through the intestine and whose nutrition can not meet their needs, especially for patients with moderate to severe catabolic conditions. Such as severe catabolic diseases, intestinal function damage, immune deficiency syndrome, patients with advanced malignant tumors, etc.
In 2020, the sales of terminal compound amino acid (15) dipeptide (2) injection in urban public hospitals, county-level public hospitals, urban community centers and township health centers in China were nearly 500 million yuan.
At present, Sichuan Kelun Pharmaceutical Co.Ltd(002422) parenteral nutrition products that have been approved for marketing are packaged in single bag (bottle), double chamber bag and three chamber bag. The differentiated product formula can meet the nutritional treatment of patients with different types and different energy needs.
Sichuan Kelun Pharmaceutical Co.Ltd(002422) said that with the continuous approval of the drug and subsequent series, the company will become a leading professional supplier of parenteral nutrition in China.
